New drug targets 'Broken Brakes' in Hard-to-Treat cancers
NCT ID NCT07303387
First seen Jan 04, 2026 · Last updated May 08, 2026 · Updated 16 times
Summary
This study tests a drug called valemetostat in people with advanced solid tumors that have certain gene changes (like SMARCB1 or ARID1A). The drug aims to reactivate protective genes to slow or stop cancer growth. About 900 adults will take the drug daily for up to 2 years, with regular checkups. The main goal is to see if tumors shrink or stop growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Léon Berard
NOT_YET_RECRUITINGLyon, 69373, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gustave Roussy
RECRUITINGVillejuif, Val de Marne, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Bergonié
NOT_YET_RECRUITINGBordeaux, 33076, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Curie
NOT_YET_RECRUITINGParis, 75005, France
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.